Leishmania vaccines: Old and New
Parasitology Today, ISSN: 0169-4758, Vol: 13, Issue: 6, Page: 236-238
1997
- 40Citations
- 19Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations40
- Citation Indexes40
- 40
- CrossRef39
- Captures19
- Readers19
- 19
Article Description
The approach to the development of a Leishmania vaccine has undergone a revolution since its early beginnings with the ancient practice of leishmazation: the inoculation of infectious parasites from an active lesion in order to produce a self-healing lesion in a healthy individual. Controlled infection has been followed by injection of killed parasites and has now progressed to subunit and naked DNA vaccines. Emanuela Handman here discusses the current studies and the future prospects for a Leishmania vaccine with a focus on cutaneous leishmaniasis. Unfortunately, what J.F. Williams said about antiparasite vaccines in 1987 (Ref. 1) is still true in 1997: ‘the reasons for optimism are less evident than the reasons for enthusiasm’.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0169475897010600; http://dx.doi.org/10.1016/s0169-4758(97)01060-0; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0030939757&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/15275077; http://linkinghub.elsevier.com/retrieve/pii/S0169475897010600; http://api.elsevier.com/content/article/PII:S0169475897010600?httpAccept=text/xml; http://api.elsevier.com/content/article/PII:S0169475897010600?httpAccept=text/plain; https://linkinghub.elsevier.com/retrieve/pii/S0169475897010600; http://dx.doi.org/10.1016/s0169-4758%2897%2901060-0; https://dx.doi.org/10.1016/s0169-4758%2897%2901060-0
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know